Past, present and future of prognostic scores in follicular lymphoma.

[1]  E. Giné,et al.  Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma , 2021, Annals of Hematology.

[2]  W. Klapper,et al.  Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma. , 2021, Blood.

[3]  M. Trněný,et al.  Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients , 2020 .

[4]  F. Cavalli,et al.  Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma , 2020 .

[5]  Ash A. Alizadeh,et al.  Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. , 2020, Blood advances.

[6]  W. Hiddemann,et al.  Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy , 2020, American journal of hematology.

[7]  C. Burton,et al.  The investigation and management of follicular lymphoma , 2020, British journal of haematology.

[8]  G. Salles,et al.  Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. , 2020, JCO oncology practice.

[9]  E. Kimby,et al.  The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy , 2020, British journal of haematology.

[10]  C. Cheng,et al.  A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era , 2020, Scientific Reports.

[11]  E. Kimby,et al.  M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy , 2020, British journal of haematology.

[12]  T. Robinson,et al.  Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation , 2019, Blood Cancer Journal.

[13]  W. Klapper,et al.  Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy , 2019, Blood.

[14]  G. Salles,et al.  Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Sancho,et al.  Recent landmark studies in follicular lymphoma. , 2019, Blood reviews.

[16]  E. Hoster,et al.  Impact of age on clinical risk scores in follicular lymphoma. , 2019, Blood advances.

[17]  E. Giné,et al.  Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era , 2018, British journal of haematology.

[18]  E. Kimby,et al.  Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. , 2018, The Lancet. Haematology.

[19]  J. Cerhan,et al.  A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. , 2018, Blood.

[20]  G. Salles,et al.  Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. , 2018, Blood.

[21]  J. Cerhan,et al.  A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts , 2018, The Lancet. Oncology.

[22]  J. Sancho,et al.  Current prognostic and predictive factors in follicular lymphoma , 2018, Annals of Hematology.

[23]  F. Angrilli,et al.  Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Klapper,et al.  Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.

[25]  D. Weinstock,et al.  The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. , 2017, Blood.

[26]  Julio Delgado,et al.  Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group , 2017, British journal of haematology.

[27]  L. Xerri,et al.  EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL , 2017 .

[28]  S. Mercadal,et al.  Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Haematology.

[29]  G. Trajkovic,et al.  FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma , 2016, International Journal of Hematology.

[30]  G. Salles,et al.  Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[32]  E. González-Barca,et al.  Clinico‐biological features, treatment and survival of 457 patients with histological Grades 3A and 1–2 follicular lymphoma mostly treated with immunochemotherapy , 2016, British journal of haematology.

[33]  Alexandra G. Smith,et al.  Predicting Time to Treatment in Follicular Lymphoma Using Population-Based Data , 2015 .

[34]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[35]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Sonali M. Smith,et al.  The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras , 2014, American journal of hematology.

[37]  J. Cerhan,et al.  Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. , 2013 .

[38]  G. Salles,et al.  Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Solal-Céligny,et al.  Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? , 2010, International journal of hematology.

[40]  M. Federico,et al.  Prognostic tools in follicular lymphomas , 2009, Expert review of hematology.

[41]  E. Steyerberg,et al.  Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[44]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[45]  E. Giné,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  E. Hoster,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect , 2006, Blood.

[47]  E. Giné,et al.  Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients , 2006, European journal of haematology.

[48]  J. Briones,et al.  Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[51]  L. Villela,et al.  Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[53]  L. Xerri,et al.  Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d‘Etude des Lymphomes Folliculaires , 2004, British journal of haematology.

[54]  T. Chisesi,et al.  Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. , 2000, Blood.

[55]  B. Coiffier,et al.  Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. López-Guillermo,et al.  The clinical significance of molecular response in indolent follicular lymphomas. , 1998, Blood.

[57]  K. Dear,et al.  The follicular non-Hodgkin's lymphomas--II. Prognostic factors: what do they mean? , 1996, European journal of cancer.

[58]  J Hermans,et al.  International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. , 1995, Blood.

[59]  W. Chan,et al.  Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. , 1995, Blood.

[60]  A. López-Guillermo,et al.  Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[62]  R. Prescott,et al.  Identification of prognostic groups in follicular lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. , 1993, Leukemia & lymphoma.

[63]  B. Nathwani,et al.  Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  B. Hoerni,et al.  Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. , 1991, European journal of cancer.

[65]  Ryan C. Leonard,et al.  Original article: The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma , 1991 .

[66]  W. Velasquez,et al.  Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  F. Berger,et al.  Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  J. Armitage,et al.  Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  D. Deakin,et al.  Maintenance chlorambucil after CVP in the management of advanced stage, low‐grade histologic type non‐Hodgkin's lymphoma: A randomized prospective study with an assessment of prognostic factors , 1988, Cancer.

[70]  M. Gospodarowicz,et al.  Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. , 1984, International journal of radiation oncology, biology, physics.

[71]  K. Lennert,et al.  The Histopathology of Malignant Lymphoma , 1975 .

[72]  C. Bloomfield,et al.  Multivariate analysis of prognostic factors in the non‐Hodgkin's malignant lymphomas , 1974, Cancer.

[73]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.